Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving hydrolase
Reexamination Certificate
2008-01-15
2008-01-15
Gitomer, Ralph (Department: 1657)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving hydrolase
C435S810000
Reexamination Certificate
active
07319017
ABSTRACT:
An in vitro method for identifying subjects at risk of heart failure following a Myocardial Infarction comprising analyzing the concentration of Matrix Metalloproteinase-9 in a bodily sample from a subject who has suffered a Myocardial Infarction and comparing this concentration with a reference for concentrations of Matrix Metalloproteinase-9 in individuals who have not suffered a Myocardial Infarction; wherein a raised concentration of Matrix Metalloproteinase-9 in the bodily sample from a subject who has suffered a Myocardial Infarction suggests the subject is at risk of heart failure.
REFERENCES:
patent: 6607894 (2003-08-01), Lopata et al.
patent: WO97/38314 (1997-10-01), None
patent: WO 00/20860 (2000-04-01), None
patent: WO 02/89656 (2002-04-01), None
Inokubo et al, “Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome,” (American Heart Journal), 2001, vol. 141, pp. 211-217.
Creemers et al, “Matrix Metalloproteinase Inhibition After Myocardial Infarction: A New Approach to Prevent Heart Failure?” (Circulation Research), 2001, vol. 89, pp. 201-210.
McLaren et al, “Prostaglandin E2-dependent Production of Latent Matrix Metalloproteinase-9 In Cultures Of Human Fetal Membranes,” (Molecular Human Reproduction), 2000, vol. 6, No. 11, pp. 1033-1040.
Altieri, P. (2003) “Metalloproteinases 2 & 9 are increased in plasma of patients with heart failure”European Journal of Clinical Investigation, 33, 648-656.
Blankenberg, Stefan et al. (2003) “Plasma Concentrations and Genetic Variations of Matrix Metalloproteinase 9 and Prognosis of Patients with Cardiovascular Disease”Circulation, 107: 1579-1585.
Bueb, Jean-Luc “Increased Levels of Matrix Metalloproteinase-9 in Patients with Acute Myocardial Infarction: No Correlation with C-Reactive Protein” ABSTRACTS-Myocardial Ischemia and Infarction.
Cleutjens, Jack P.M. & Creemers, Esther, EJM (2002) “Integration of Concepts: Cardiac Extracellular Matric Remodeling After Myocardial Infarction”Journal of Cardiac Failure, 8(6): S344-S348.
Ducharme, Anique, et al. (2000) “Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction”The Journal of Clinical Investigation, 106(1): 55-62.
Galis, Zorina S. & Khatri, Jaikirshan J. (2002) “Matrix Metalloproteinases in Vascular Remodeling and Atherogenesis”Circ Res.90:251-262.
Galt, Spencer W. et al. (2001) “Differential Regulation of Matrix Metalloproteinase-9 by Monocytes Adherent to Collagen and Platelets”Circ Res., 89: 509-516.
Inokubo, Yoichi et al. (2001) “Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome”American Heart Journal, 141: 211-217.
Jugdutt, Bodh (2006) “Matrix Metalloproteinases as Markers of Adverse Remodeling After Myocardial Infarction”Journal of Cardiac Failure12(1):73-76.
Jugdutt, Bodh (2003) “Ventricular Remodeling After Infarction and the Extracellular Collagen Matrix”Circulation, 108:1395-1403.
Kai, Hisashi, et al (1998) “Peripheral Blood Levels of Matrix Metalloproteases-2 and -9 Are Elevated in Patients with Acute Coronary Syndromes”JACC, 32(2): 236-372.
Lehoux, Stephanie, et al. (2004) “Pressure-Induced Matrix Metalloproteinase-9 Contributes to Early Hypertensive Remodeling”Circulation, 109: 1041-1047.
Li, Yun You et al. (2000) “Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling”Cardiovascular Research46: 214-224.
Li, Yun You et al. (2002) “MMP inhibition modulates TNF-α transgenic mouse phenotype early in the development of heart failure”Am. J Physiol Heart Circ Phusiol282: H983-H989.
Li, Yun You et al. (1998) “Differential Expression of Tissue Inhibitors of Metalloproteinases in the Failing Human Heart”Circulation, 98: 1728-1734.
Libby, Peter and Lee, Richard T. (2000) “Matrix Matters”Circulation, 102:1874-1876.
Mann, Douglas L. (2002) “Tumor Necrosis Factor-Induced Signal Transduction and Left Ventricular Remodeling”Journal of Cardiac Failure, 8(6): S379-S386.
Manolio, Teri (2003) “Novel Risk Markers and Clinical Practice”N Engl J Med, 349(17): 1587-1589.
Mukherjee, Rupak et al. (2003) “Myocardial Infarct Expansion and Matrix Metalloproteinase Inhibition”Circulation, 107: 618-625.
Nian, Min et al. (2004) “Inflammatory Cytokines and Postmyocardial Infarction Remodeling”Circ Res., 94: 1543-1553.
Oak, Min-Ho et al. (2004) “Red Wine Polyphenolic Compounds Strongly Inhibit Pro-Matrix Metalloproteinase-2 Expression and Its Activation in Response to Thrombin via Direct Inhibition of Membrane Type 1-Matrix Metalloproteinase in Vascular Smooth Muscle Cells”Circulation, 110: 1861-1867.
Pitt, Geoffrey “Matrix Metalloproteinases Are Molecules of the Moment” theheart.org, Sep 13, 2000 14:18:47.
Reinhardt, D. et al. (2002) “Cardiac remodeling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors in MMP”Heart, 88:525-530.
Renko, J. et al. (2004) “Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarcation”Scand. J. Clin Lab Invest, 64: 255-262.
Reynolds, Mark A. et al. (2003) “Early Biomarkers of Stroke”Clinical Chemistry49(10): 1733-1739.
Romanic, Anne M., et al. (2002) “Myocardial protection form ischemia/reperfusion injury by targeted deletion of matrix metalloproteinase-9”Cardiovascular Research, 54:549-558.
Shiomi, Tetsuya et al. (2004) “Overexpression of Glutathione Peroxide Prevents Left Ventricular Remodeling and Failure After Myocardial Infarction in Mice”Circulation, 109:544-549.
Spinale, Francis G. (2002) “Matrix Metallopoteinases: Regulation and Dysregulation in the Failing Heart”Circ Res.90:520-530.
Spinale, Francis G. (2002) “Bioactive Peptide Signaling Within the Myocardial Interstitium and the Matrix Metalloproteinases”Circ Res.91:1082-184.
Squire, Iain B. et al. (2004) “Plasma MMP-9 and MMP-2 Following Acute Myocardial Infarction in Man: Correlation with Echocardiographic and Neurohumoral Parameters of Left Ventricular Dysfunction”Journal of Cardiac Failure, 10(4): 328-333.
Sundström, Johan et al. (2004) “Relations of Plasma Matrix Metalloproteinase-9 to Clinical Cardiovascular Risk Factors and Echocardiographic Left Ventricular Measures”Circulation, 109: 2850-2856.
Thompson, Matt M. and Squire, Iain B. (2002) “Matrix metalloproteinase-9 expression after myocardial infarction: physiological or pathological?”Cardiovascular Research, 54: 495-498.
Tsuruda, Toshihiro, et al. (2002) “Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases”Circ. Res., 91: 1127-1134.
Wagner, et al. (2006) “Matrix Metalloproteinase-9 Is a Marker of Heart Failure After Acute Myocardial Infarction”Journal of Cardiac Failure, 12(1):66-72.
Wilson, Eric M. et al. (2003) “Region- and Type-Specific Induction of Matrix Metalloproteinases in Post-Myocardial Infarction Remodeling”Circulation, 107: 2857-2863.
Wilson, Eric M. et al. (2002) “Plasma Matrix Metalloproteinase and Inhibitor Profiles in Patients with Heart Failure”Journal of Cardiac Failure, 8(6):390-398.
Yarbrough, William M. et al. (2003) “Selective Targeting and Timing of Matrix Metalloproteinase Inhibition in Post-Myocardial Infarction Remodeling”Circulation, 108:1753-
Centre de Recherche Public de la Santé
Gitomer Ralph
Quine Intellectual Property Law Group P.C.
Wood Amanda P.
LandOfFree
Monitoring heart failure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Monitoring heart failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Monitoring heart failure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2809064